QuantSignals › Forecasts › RMD
KATY's daily model path, its record on RMD, and the options read. Prices as of the Nov 10, 2026 close · page updated Nov 10, 2026.
Last close
$234.11
Nov 10, 2026 · −0.69% on the day
KATY call
SELL
run Nov 6, 2026
Path end (20 sessions)
$231.69
−1.53% from $235.30
Path range
−2.7% to −1.4%
lowest and highest point of the path
Replay record on RMD
10/13 hits
76.9% · 3 misses
KATY's latest public daily path for ResMed, from its run on Nov 6, 2026, points down, which KATY labels SELL. Starting from the $235.30 close, the path ends 20 sessions later near $231.69 (−1.53%), around Dec 4, and ranges between −2.70% and −1.45% along the way. That is a model path, not a price target.
Since that run, RMD has closed at $234.11 on Nov 10, 2026, −0.51% from the start, 2 of 20 sessions in. So far the move agrees with the path. The call is scored after session 20.
On RMD, KATY's replay record is 10 hits and 3 misses in 13 tested calls (76.9%), above its 50.1% rate across all tickers. Its most recent completed replay call expected −2.19% and RMD moved +2.28%: a miss on direction.
Daily closes, with KATY's Nov 6, 2026 path drawn from its start close to its end point; the shaded wedge spans the path's lowest and highest points.
The KATY apps and extension show the newest RMD path as soon as it runs, with the full step-by-step line on the chart. They are free to install; live forecasts need KATY Premium or an FST membership.
Every public RMD path this page has captured, scored on the close 20 sessions after its start: a BUY is a hit if that close is higher, a SELL if it is lower.
| Run | Call | Start close | Path end | Outcome at 20 sessions |
|---|---|---|---|---|
| Nov 6, 2026 | SELL | $235.30 | $231.69 (−1.53%) | Open, 2/20 sessions · −0.51% so far |
10 hits, 3 misses and 2 neutral in 13 replayed RMD calls (76.9% on direction; 69.2% finished inside the 1.5% band; average path error 4.2%). Across all tickers KATY's replay hit rate is 50.1% over 1,023 calls (BUY > +1.5%, SELL < -1.5% on the 20-step path). Replays re-run the model on past data it did not see; they are not live trades.
KATY re-forecast the 20 sessions that just finished without seeing them. It expected −2.19%; the actual move was +2.28% (direction miss, average path error 5.78%).
| Step | Session | Model path | Actual close | Path vs actual |
|---|---|---|---|---|
| 1 | Oct 12, 2026 | $229.89 | $234.60 | −2.01% |
| 5 | Oct 16, 2026 | $227.21 | $238.97 | −4.92% |
| 10 | Oct 23, 2026 | $227.78 | $252.86 | −9.92% |
| 15 | Oct 30, 2026 | $227.85 | $229.94 | −0.91% |
| 20 | Nov 6, 2026 | $225.02 | $235.30 | −4.37% |
KATY's latest public daily path for RMD (run Nov 6, 2026) is SELL: from $235.30 it ends near $231.69 (−1.53%) after 20 sessions. It is a model path, not a price target. The newest path is in the KATY apps (free to install; live forecasts need KATY Premium or an FST membership).
In replay, KATY called the direction of RMD right 10 times and wrong 3 times out of 13 tested calls (76.9%). Public calls on this page are scored after 20 sessions and listed above, misses included.
KATY is a time-series foundation model that reads the recent daily bars of RMD and draws the most likely path for the next 20 sessions. A path that ends more than 1.5% up is a BUY, more than 1.5% down a SELL, and anything in between is NEUTRAL. It is not investment advice.
KATY draws this forecast on your own charts: in TradingView with the Chrome extension, or on your phone. The extension and apps are free to install; live forecasts need KATY Premium or an FST membership.
Healthcare & biotech
Most viewed
Not investment advice. KATY's output is a model path, not a price target and not a recommendation to buy or sell. Model forecasts are often wrong; the hit and miss counts on this page are shown so you can judge that yourself. Trading involves risk of loss. Data from QS Research; prices are daily closes and may lag.